celecoxib has been researched along with Hepatopulmonary Syndrome in 1 studies
Hepatopulmonary Syndrome: A syndrome characterized by the clinical triad of advanced chronic liver disease, pulmonary vascular dilatations, and reduced arterial oxygenation (HYPOXEMIA) in the absence of intrinsic cardiopulmonary disease. This syndrome is common in the patients with LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CC | 1 |
| Lee, WS | 1 |
| Hsieh, HG | 1 |
| Chuang, CL | 1 |
| Huang, HC | 1 |
| Lee, FY | 1 |
| Lee, SD | 1 |
1 other study available for celecoxib and Hepatopulmonary Syndrome
| Article | Year |
|---|---|
Selective cyclooxygenase inhibition by SC-560 improves hepatopulmonary syndrome in cirrhotic rats.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Disease Models, Animal; Down-Regula | 2017 |